Horizon Europe Prof. Ayal Hendel

Congratulations to Prof. Ayal Hendel (Bar-Ilan University) for being part of EASYGEN, a prestigious €8M Horizon Europe consortium coordinated by Fresenius SE & Co. KGaA.
Together with leading partners including Fraunhofer IZI, University of Glasgow and University of Navarra, the project aims to revolutionize CAR-T therapy by making it safer, faster, and more accessible.
Proud to see Bar-Ilan at the forefront of such impactful international collaboration!
🔗 Read more - https://lnkd.in/dsQ3F5Xh

Prof. Handel was awarded for his pioneering work in genetic editing technologies to cure blood and immune system diseases. This year, he published two groundbreaking papers. In the first study, published in the journal Molecular Therapy Nucleic Acids, he presented preclinical evidence for the genetic correction of Bubble Boy Disease, a genetic disease characterized by the absence of an immune system. In the second study, published in the journal Nature Communications, Prof. Handel developed an innovative genetic editing method that replaces a faulty DNA segment with a correct one while removing the defective DNA from the genome. This method is preferable to existing genetic editing methods and may allow more efficient treatment of genetic diseases. To learn more about Prof. Handel and his research, you can watch this video: https://www.youtube.com/watch?v=oNuncsZQHOw&t=1s